Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Upgraded by Wall Street Zen

Key Points

• Teva Pharmaceutical Industries has received an upgrade from Wall Street Zen, increasing its stock rating from "buy" to "strong-buy."
• Analysts have mixed opinions on Teva's stock, with two ratings as Strong Buy, six as Buy, and one as Sell, leading to a current consensus rating of "Buy" with a price target of $25.57.
• The company reported earnings of $0.66 per share for its last quarter, which exceeded analysts' expectations, although revenue fell slightly short of estimates at $4.18 billion.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Saturday.

TEVA has been the subject of a number of other reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an "overweight" rating in a research note on Friday, October 3rd. Finally, UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, September 24th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $25.57.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $20.01 on Friday. The company has a 50-day moving average price of $18.51 and a two-hundred day moving average price of $16.95. The stock has a market cap of $22.95 billion, a price-to-earnings ratio of -125.04, a price-to-earnings-growth ratio of 1.16 and a beta of 0.71. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's revenue for the quarter was up .3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Insider Buying and Selling

In related news, insider Placid Jover sold 6,053 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Company insiders own 0.49% of the company's stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds have recently made changes to their positions in TEVA. GAMMA Investing LLC lifted its position in shares of Teva Pharmaceutical Industries by 804.7% in the 1st quarter. GAMMA Investing LLC now owns 67,474 shares of the company's stock valued at $1,037,000 after acquiring an additional 60,016 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Teva Pharmaceutical Industries by 0.8% in the 1st quarter. Rhumbline Advisers now owns 281,062 shares of the company's stock valued at $4,320,000 after acquiring an additional 2,128 shares in the last quarter. Yousif Capital Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 1.9% in the 1st quarter. Yousif Capital Management LLC now owns 55,986 shares of the company's stock valued at $861,000 after acquiring an additional 1,033 shares in the last quarter. Handelsbanken Fonder AB purchased a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at approximately $243,000. Finally, Fifth Third Bancorp lifted its position in shares of Teva Pharmaceutical Industries by 17.4% in the 1st quarter. Fifth Third Bancorp now owns 21,985 shares of the company's stock valued at $338,000 after acquiring an additional 3,265 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.